Thomas Martin, MD
Dr Martin is a Clinical Professor of Medicine and Associate Chief the Division of Hematology/Oncology, and Co-Lead of the Cancer Immunology and Immunotherapy Program in the Helen Dillier Family Comprehensive Cancer Center at the University of California, San Francisco. Dr Martin has been a thought leader and an invited speaker at national and international meetings. Dr. Martin serves as co-Lead of the Immunotherapy sub-committee of the International Myeloma Foundation. Dr Martin has been principal investigator (PI) on over 30 clinical trials. Dr Martin recently received a 4.6 million grant from the California Institute for Regenerative Medicine to investigate a novel BCMA-targeted CART-cell therapy. Dr Martin is developing a investigator-initiated trial testing the safety and efficacy of a novel CELMoD with Talquetamab. Dr. Martin continues to be very active in immunotherapy trials including cellular therapy trials in ND and RRMM.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:sanofiTopic:isatuximabDate added:03/26/2024Date updated:03/26/2024Relationship end date:03/31/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:JanssenTopic:immunotherapyDate added:03/26/2024Date updated:03/26/2024Relationship end date:03/25/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GSKTopic:BelantamabDate added:03/26/2024Date updated:03/26/2024Relationship end date:03/26/2025
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:PfizerTopic:ImmunotherapyDate added:03/26/2024Date updated:03/26/2024Relationship end date:03/25/2024